Table 1

Baseline characteristics, interventions and outcomes of study population

MIMICeICU-CRDPLAGH-ICUdbAUMCdbUCIHJ23db
CountryUSAUSAChinaNetherlandsSpain
ICU admissions, No38 508132 99463 51520 1274238
Male sex, No (%)21 793 (56.59)71 983 (54.15)38 155 (60.07)12 807 (65.16)2730 (64.42)
Age, years, median (IQR)65.70 (52.40–77.90)65.00 (53.00–76.00)56.89 (45.89–66.77)Not available*63.00 (50.00–73.00)
Admission type, No (%):
Elective6039 (15.83)24 631 (18.52)29 398 (46.29)14 429 (71.69)179 (4.22)
Emergency:32 122 (84.17)108 363 (81.48)34 117 (53.71)5698 (28.31)4059 (95.78)
 Via emergency department19 152 (49.77)69 077 (51.94)29 790 (46.90)2515 (12.50)2220 (52.38)
 Via other (eg, ward)13 248 (34.40)39 312 (29.56)4327 (6.81)3183 (15.81)1839 (43.39)
Cardiac surgery, No (%)7606 (19.75)12 103 (9.10)7265 (11.44)7036 (34.96)0 (0)
Mechanical ventilation,
 No (%)19 156 (49.78)49 159 (36.96)Not available†14 055 (69.83)1844 (43.51)
 Duration—hours, median (IQR)19.00 (6.53–82.25)27.82 (11.28–74.35)Not available†Not available94.65 (28.40–256.82)
RRT,
No (%)
1790 (4.65)2154 (4.38)‡Not available†918 (4.56)343 (8.09)
Crystalloid administration,
 No (%)27 218 (70.74)Not available§52 165 (82.13)19 079 (94.79)1894 (44.69)
 mL, median (IQR)2000 (900–3650)Not available§1500 (750–2500)1500 (1000–2469)1000 (500–1500)
Colloid administration, No (%)2587 (6.72)Not available§19 527 (30.74)8642 (42.94)217 (5.12)
Packed red blood cell transfusion, No (%)12 361 (32.12)Not available§8584 (13.51)5435 (27.00)1007 (23.76)
ICU length of stay, hours, median (IQR)50.30 (28.50–98.20)39.00 (21.00–71.00)95.01 (45.67–173.16)25.00 (20.00–73.00)93.70 (48.20–191.52)
ICU mortality, No (%)2947 (7.66)7618 (5.73)3743 (5.89)1929 (9.58)619 (14.61)
  • *AUMCdb only contains age categories.

  • †Data not recorded in PLAGH-ICUdb.

  • ‡Data from subset of eICU-CRD sites with reliable data regarding RRT therapy.

  • §Excluded due to poor data collection regarding IV fluid and PRBC administration.

  • ICU, intensive care unit; PRBC, packed red blood cell; RRT, renal replacement therapy.